Skip to main content
SpringerLink
Log in

Treatment with long acting repeatable bromocriptine (Parlodel-LAR*) in patients with macroprolactinomas: long-term study in 29 patients

  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

The aim of the study was to evaluate the short term and long-term effects of long acting repeatable bromocriptine (=Parlodel-LAR*) in patients with macroprolactinomas. Twenty-nine patients (15 men and 14 women) aged 42±2.7 (M±SEM) years were injected with Parlodel-LAR* every 4 weeks during 3.3±0.3 years. The starting dose was 50 mg/injection, then it was increased to 100 mg in 11 patients and 150 mg in 9 patients. PRL levels decreased in all but one patient 4 weeks after the first injection (270±59 vs 934±210 ng/ml, p<0.001), then became less than 20 ng/ml in 20/29 (69%) patients and finally became undetectable or low in 13/29 (45%) patients. Visual field defects were present in 12/29 patients before treatment. In 11/12 patients, treatment with Parlodel-LAR* resulted in an improvement and complete correction of visual field defects was observed in 8/12 patients. Adenoma size (2.5±0.2 cm before treatment) was reduced by at least 20% in 24/29 (83%) patients. Disappearance of adenoma was observed on CT scan in 8/29 (28%) patients after 28.7 ±5.3 months of treatment. Minor side effects occurred in 20 patients after the first injection then disappeared in 18 patients within the following 6 months of treatment. One patient had rhinorrhea after 3 months of treatment. Treatment with Parlodel-LAR* results in beneficial short-term effects (with rapid correction of recent onset visual field defects) and long-term effects (which can include complete disappearance of adenoma on CT scan evaluation) in patients with macroprolactinomas.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bevan J., Webster J., Burke C, Scanlon M. Dopamine agonists and pituitary tumor shrinkage. Endocr. Rev. 13: 220, 1992.

    Article  PubMed  CAS  Google Scholar 

  2. Ciccarelli E., Miola C., Grottoli S., Lancranjan I., Camanni F. Chronic treatment with long-acting injectable repeatable bromocriptine and comparison with oral bromocriptine in hyperprolactinemic patients. J. Endocrinol. Invest., 14 (Suppl. 1): abstract OC 31, 1991.

    Google Scholar 

  3. Ciccarelli E., Miola C., Grottoli S., Avataneo T., Lancranjan I., Camanni F. Long-term therapy of patients with macroprolactinoma using repeatable injectable bromocriptine. J.Clin. Endocrinol. Metab. 76: 484, 1993.

    PubMed  CAS  Google Scholar 

  4. Maraschini C, Moro M., Masala A., Toja P., Alagna S., Brunani A., Rovasio P.P., Givanni A., Lancranjan I., Cavagnini F. Chronic treatment with Parlodel-LAR of patients with prolactin-secreting tumours. Different responsiveness of micro- and macroprolactinomas. Acta Endocrinol. (Copenh.) 125: 494, 1991.

    CAS  Google Scholar 

  5. Haase R., Jaspers C., Schulte H.M., Lancranjan I., Pfingsten H., Orri-Fend M., Reinwein D., Benker G. Control of prolactin-secreting macroadenomas with parenteral, long-acting bromocriptine in 30 patients treated for up 3 years. Clin. Endocrinol. (Oxf.) 33: 165, 1993.

    Article  Google Scholar 

  6. Brue T., Dewailly D., Lancranjan I., Roger P., Louvet J.P, Jaquet P. A long-acting repeatable form of bromocriptine as long-term treatment of prolactin-secreting macroadenomas: a multicenter study. Fertil. Steril. 57: 74, 1992.

    PubMed  CAS  Google Scholar 

  7. Beckers A., Petrossians P., Abs R., Flandroy P., Stadnik T., de Longueville M., Lancranjan I., Stevenaert A. Treatment of macroprolactinomas with the long-acting and repeatable form of bromocriptine: a report on 29 cases. J. Clin. Endocrinol. Metab. 75: 275, 1992.

    PubMed  CAS  Google Scholar 

  8. Hardy J. Le prolactinome. Aspects chirurgicaux. Neurochirurgie 27 (Suppl. 1): 41, 1981.

    PubMed  Google Scholar 

  9. Van Schaardenburg D., Van Seters A.P. Bromocriptine therapy for non functioning adenomas. Clin Endocrinol. (Oxf.) 30: 475, 1989.

    Article  Google Scholar 

  10. Van’t Verlaat J., Lancranjan I., Hendricks M., Croughs R. Primary treatment of macroprolactinomas with Parlodel LAR*. Acta Endocrinol. (Copenh.) 119: 51, 1988.

    Google Scholar 

  11. Kocijancic A., Prezelj J., Vrohovec I., Lancranjan I. Parlodel LAR* in the treatment of macroprolactinomas. Acta Endocrinol. (Copenh.) 122: 272, 1990.

    CAS  Google Scholar 

  12. Schettini G., Lombardi G., Merola B., Colao A., Miletto P., Caruso E., Lancranjan I. Rapid and long-lasting suppression of prolactin secretion and shrinkage of prolactinomas after injection of long-acting repeatable form of bromocriptine (Parlodel LAR*). Clin. Endocrinol. (Oxf.) 33: 161, 1990.

    Article  CAS  Google Scholar 

  13. Bronstein M., Musolino O., Monteiro M., Marino R. Treatment of macroprolactinomas with a long-acting parenteral and repeatable new form of bromocriptine. Advances in the Biosciences (Pergamon Press) 69: 313, 1988.

    Google Scholar 

  14. Molitch M.E., Elton R.L., Blackwell R.E., Caldwell B., Chang R.J., Jaffe R., Joplin G., Robbins R.J., Tyson J., Thorner M.O. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J. Clin. Endocrinol. Metab. 60: 698, 1985.

    Article  PubMed  CAS  Google Scholar 

  15. Van’t Verlaat J.W., Croughs R.J.M., Hendriks M.J., Bosma N.J. Results of primary treatment with bromocriptine of prolactinomas with extrasellar extension. Can. J. Neurol. Sci. 17: 71, 1990.

    Google Scholar 

  16. Liuzzi A., Dallabonzana D., Oppizzi. G., Verde G.G., Cozzi R., Chiodini P., Luccarelli G. Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N. Engl. J. Med. 313: 656, 1985.

    Article  PubMed  CAS  Google Scholar 

  17. Van der Lely A., Brownell J., Lamberts S.W.J. The efficacy and tolerability of CV 205–502 (a non-ergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine. J. Clin. Endocrinol. Metab. 72: 1136, 1991.

    Article  PubMed  Google Scholar 

  18. Kvistborg A., Halse J., Bakke S., Bjoro T., Hansen E., Djoseland O., Brownell J., Jervell J. Long-term treatment of macroprolactinomas with CV 205–502. Acta Endocrinol. (Copenh.) 723: 301, 1993.

    Google Scholar 

  19. Vance M. L, Upper M., Klibanski A., Biller B.M.K., Samaan N.A., Molitch M.E. Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamin agonist CV 205–502. Ann. Intern. Med. 772: 668, 1990.

    Article  Google Scholar 

  20. Serri O., Beauregard H., Lesage J., Pedneault L., Comtois R., Jilwan N., Somma M., Vachon L., Brownell J. Long term treatment with CV 205–502 in patients with prolactin-secreting pituitary macroadenomas. J. Clin. Endocrinol. Metab. 71: 682, 1990.

    Article  PubMed  CAS  Google Scholar 

  21. Ferrari C, Piscitelli G., Crosignani P. Cabergoline: a new drug for the treatment of hyperprolactinaemia. Hum. Reprod. 10: 1647, 1995.

    PubMed  CAS  Google Scholar 

  22. Berezin M., Shimon I., Hadani M. Prolactinoma in 53 men: clinical characterictics and modes of treatment (male prolactinoma). J. Endocrinol. Invest. 18: 436, 1995.

    Article  PubMed  CAS  Google Scholar 

  23. Lengyel A.M., Vieira J.G., Mussio W., Lancranjan I., Imamura P. Long-acting injectable Bromocriptine (Parlodel-LAR*) in the chronic treatment of prolactin-secreting macroadenomas. Fertil. Steril. 59: 980, 1993.

    PubMed  CAS  Google Scholar 

  24. Ferrari C., Paracchi A., Mattei A.M., de Vincentiis S., dAlberton A., Crosignani P. Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol. (Copenh.) 126: 489, 1992.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology, CHU Purpan, Place Baylac, 31059, Toulouse, France

    S. I. Jamrozik, A. P. Bennet, F. Tremollieres, F. Saint-Martin, S. Dumoulin, M. Valat-Coustols, I. de Glisezinski & J. P. Louvet M.D.

  2. Laboratoires Sandoz, Lyon, France

    A. James-Deidier

  3. Departments of Neurosurgery, CHU Purpan, Toulouse, France

    M. Tremoulet

  4. Departments of Neuroradiology, CHU Purpan, Toulouse, France

    C. Manelfe

Authors
  1. S. I. Jamrozik
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. P. Bennet
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. James-Deidier
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. Tremollieres
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F. Saint-Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S. Dumoulin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Valat-Coustols
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. I. de Glisezinski
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M. Tremoulet
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. C. Manelfe
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. J. P. Louvet M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

These data were presented at the IIIrd European Congress of Endocrinology, Amsterdam, July 18–22, 1994.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jamrozik, S.I., Bennet, A.P., James-Deidier, A. et al. Treatment with long acting repeatable bromocriptine (Parlodel-LAR*) in patients with macroprolactinomas: long-term study in 29 patients. J Endocrinol Invest 19, 472–479 (1996). https://doi.org/10.1007/BF03349893

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03349893

Key-words

Search

Navigation